Andliena Tahiri

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 6

Top Topics

Epidermal Growth Factor Receptor

Metastatic Breast Cancer

High Throughput

Top Venues

Molecular oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Lilly Anne Torland, Xiaoran Lai, Surendra Kumar, Margit H Riis, Jürgen Geisler, Torben Lüders, Xavier Tekpli, Vessela Kristensen, Kristine Sahlberg, Andliena Tahiri
Benign breast tumors may arise on different immunological backgrounds. Molecular oncology (2024)
Lisa Svartdal Normann, Mads Haugland Haugen, Vesa Hongisto, Miriam Ragle Aure, Suvi-Katri Leivonen, Vessela N Kristensen, Andliena Tahiri, Olav Engebraaten, Kristine Kleivi Sahlberg, Gunhild Mari Mælandsmo
High-throughput screen in vitro identifies dasatinib as a candidate for combinatorial treatment with HER2-targeting drugs in breast cancer. PloS one 18 (1) (2023)
Lisa Svartdal Normann, Mads Haugland Haugen, Vesa Hongisto, Miriam Ragle Aure, Suvi-Katri Leivonen, Vessela N Kristensen, Andliena Tahiri, Olav Engebraaten, Kristine Kleivi Sahlberg, Gunhild Mari Mælandsmo
High-throughput screen in vitro identifies dasatinib as a candidate for combinatorial treatment with HER2-targeting drugs in breast cancer. PloS one 18 (1) (2023)
Lisa Svartdal Normann, Mads Haugland Haugen, Vesa Hongisto, Miriam Ragle Aure, Suvi-Katri Leivonen, Vessela N Kristensen, Andliena Tahiri, Olav Engebraaten, Kristine Kleivi Sahlberg, Gunhild Mari Mælandsmo
High-throughput screen in vitro identifies dasatinib as a candidate for combinatorial treatment with HER2-targeting drugs in breast cancer. PloS one 18 (1) (2023)
Lisa Svartdal Normann, Mads Haugland Haugen, Vesa Hongisto, Miriam Ragle Aure, Suvi-Katri Leivonen, Vessela N Kristensen, Andliena Tahiri, Olav Engebraaten, Kristine Kleivi Sahlberg, Gunhild Mari Mælandsmo
High-throughput screen in vitro identifies dasatinib as a candidate for combinatorial treatment with HER2-targeting drugs in breast cancer. PloS one 18 (1) (2023)
Lisa Svartdal Normann, Mads Haugland Haugen, Vesa Hongisto, Miriam Ragle Aure, Suvi-Katri Leivonen, Vessela N Kristensen, Andliena Tahiri, Olav Engebraaten, Kristine Kleivi Sahlberg, Gunhild Mari Mælandsmo
High-throughput screen in vitro identifies dasatinib as a candidate for combinatorial treatment with HER2-targeting drugs in breast cancer. PloS one 18 (1) (2023)